Sector News

Categories

Borderless Insights

Image
Ditch Your CV Biases: Finding Your Next Leader Demands a Storyteller’s Curiosity
Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?

Stryker to build new innovation centre in Cork

September 23, 2014
Life sciences
US medical technologies company Stryker is to build a new 44,000 square foot surgical innovation centre in Cork, which will combine all Ireland-based research and new product development activities and support functions within one purpose-built facility. Construction is set to commence in the last months of this year, with completion expected in Q4 2015.
 
“This state-of-the-art facility will drive innovation by giving us the ability to design, develop and test new products in conditions that mimic real life,” Stryker Instruments President Jim Heath said.
 
The innovation centre, which Stryker says will fuel future growth, will focus on the research and development of products, technologies and solutions to reduce surgical procedure time and healthcare costs while improving surgical precision and clinical outcomes in the areas of bone cutting, soft tissue dissection and adjacent areas across a broad spectrum of surgical specialities and procedures. It is being constructed with the support of the IDA.
 
Stryker says the facility will feature state-of-the-art R&D facilities for product design and process development and a customer experience laboratory that will allow engineers and surgeons to test and evaluate new ideas, technology and product designs in a simulated operating room and surgical environment.
Stryker first came to Ireland in 1998 and now employs over 2,200 people at four sites between Cork and Limerick, including over 150 people in research and development.
 
Source: Irish Times

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

Read more
September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

Read more
September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

Read more
More news

How can we help you?

We're easy to reach